- Women over 40 face unique weight-loss challenges including declining estrogen, loss of muscle mass, and increased insulin resistance
- GLP-1 medications show strong efficacy in women over 40, with clinical trial data showing no significant difference in response by age group
- Phentermine and Contrave remain effective options, though cardiovascular screening is more important as women age
- PEAK tailors medication selection to each patient’s hormonal status, metabolic profile, and health history
For many women, the 40s mark a turning point in weight management. Strategies that worked in your 20s and 30s — cutting portions, adding a few extra workouts — stop producing results. This is not a discipline problem. It is a physiological shift driven by hormonal changes, metabolic slowdown, and changing body composition. The good news: prescription weight-loss medications can address these changes directly, and clinical data shows women over 40 respond well to evidence-based treatment.
Why weight loss changes after 40
Starting in your 30s, your basal metabolic rate — the number of calories your body burns at rest — decreases roughly 1–2% per decade. That may sound small, but it compounds. By your mid-40s, you are burning meaningfully fewer calories at rest than you did a decade earlier, even at the same body weight.
Compounding this metabolic slowdown is sarcopenia: the gradual loss of lean muscle mass. Without resistance training, women lose approximately 3–8% of muscle mass per decade after 30. Less muscle means a lower resting metabolic rate, which means fewer calories burned throughout the day — even during sleep.
Fat distribution also shifts. Before menopause, women tend to store fat subcutaneously (hips, thighs). During perimenopause and menopause, fat storage shifts toward visceral (abdominal) fat, which is metabolically active and associated with insulin resistance, cardiovascular risk, and inflammation.
Caloric restriction alone becomes less effective after 40 and can actually worsen muscle loss, further slowing metabolism. This is why the “eat less, move more” advice that may have worked earlier often backfires in midlife. Medical treatment addresses the underlying biology, not just the calorie math.
Hormonal factors
Perimenopause typically begins in the early-to-mid 40s, though timing varies. During this transition, estrogen and progesterone levels fluctuate unpredictably before eventually declining. These hormonal shifts affect weight in several direct ways.
Declining estrogen promotes visceral fat storage and increases insulin resistance. Estrogen plays a protective role in metabolic health, and as levels fall, women become more susceptible to weight gain — particularly around the midsection — even without changes in diet or activity.
Hunger hormone disruption. Changes in leptin and ghrelin signaling during perimenopause affect hunger and satiety cues. Many women report feeling hungrier or less satisfied after meals, which is driven by biology rather than willpower.
Thyroid changes. Subclinical hypothyroidism becomes more common in women over 40, which can slow metabolism and make weight loss more difficult. Thyroid screening is an important part of any thorough evaluation.
Cortisol and stress. Sleep disruption — common during perimenopause — elevates cortisol levels. Chronic cortisol elevation directly promotes visceral fat storage and increases cravings for calorie-dense foods. This compounds the hormonal changes already occurring.
Hormone replacement therapy (HRT) can help with menopausal symptoms and may reduce some visceral fat accumulation, but it is not a weight-loss treatment. HRT is best used alongside dedicated weight-loss medication when appropriate. Your clinician can help determine whether HRT is relevant to your overall treatment plan.
Best medication options
Several prescription medications have demonstrated strong efficacy for women over 40. The right choice depends on your metabolic profile, hormonal status, current medications, and health history.
GLP-1 medications (Wegovy, Zepbound)
GLP-1 receptor agonists represent the highest-efficacy option currently available. Subgroup analyses from the STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) included women ages 40–65 with comparable results to younger cohorts. If a GLP-1 is not producing the expected results, see what to do when a GLP-1 doesn’t work. These medications are particularly well-suited for women over 40 because they address insulin resistance — a core issue in this age group.
Zepbound (tirzepatide) may be especially beneficial for women with metabolic syndrome, as the dual GIP/GLP-1 mechanism targets both glucose regulation and fat metabolism. In clinical trials, Wegovy produces approximately 15% weight loss (STEP 1, 68 weeks) and Zepbound produces up to 22.5% weight loss of body weight (SURMOUNT-1, 72 weeks).
Phentermine
Phentermine remains an effective short-term appetite suppressant. For women over 40, cardiovascular screening before starting is particularly important since hypertension becomes more common with age. A typical 12-week course can provide significant momentum and jump-start a treatment plan. Its low cost makes it accessible regardless of insurance status. For detailed pricing, see our phentermine cost and insurance guide.
Contrave (naltrexone-bupropion)
Contrave is a strong option for women who struggle with emotional eating patterns, which can intensify during perimenopause. The bupropion component may also help with mood changes that accompany hormonal shifts. Review the full list of Contrave side effects before starting. Unlike phentermine, Contrave has no cardiovascular stimulant effect, making it a suitable option for women who cannot take stimulant-based medications.
Metformin (off-label adjunct)
While not a weight-loss medication per se, metformin addresses insulin resistance directly and is commonly used alongside dedicated weight-loss medications. It is well-studied in women with a history of PCOS and can provide a metabolic foundation for other treatments.
Medication choice may differ based on what you are already taking. Women over 40 are more likely to be on HRT, antidepressants, or blood pressure medications, all of which affect which weight-loss medications are appropriate. This is why a full medication review is part of every PEAK evaluation.
Safety considerations
Safety screening becomes more important with age. PEAK takes a thorough approach to evaluating every patient, but women over 40 should be aware of these specific considerations.
- Cardiovascular screening. Blood pressure, heart rate, and lipid panel evaluation are essential before starting any weight-loss medication. Hypertension and dyslipidemia become more common after 40, and these affect medication selection.
- Bone density. Rapid weight loss can accelerate bone loss, which is already a concern for women approaching menopause. Calcium and vitamin D monitoring are important during treatment, and your clinician may recommend a DEXA scan as a baseline.
- Drug interactions. A review of all current medications is critical. Common medications in this age group — antihypertensives, SSRIs, thyroid medication — can interact with weight-loss drugs.
- Phentermine-specific. Avoid with uncontrolled hypertension or cardiovascular disease. Cardiovascular monitoring at every visit is standard when prescribing phentermine.
- Contrave-specific. Avoid with seizure history or uncontrolled hypertension. The bupropion component lowers the seizure threshold.
- GLP-1-specific. Generally well-tolerated across age groups. Gallbladder risk is slightly elevated, particularly during rapid weight loss. Gastrointestinal side effects are most common during dose escalation.
- Regular labs during treatment. Metabolic panel, thyroid function, and lipid panel monitoring at regular intervals throughout treatment ensures safety and allows for timely adjustments.
Weight loss after 40 is not about trying harder. It is about treating the biology that has changed.
Lifestyle synergies
Medication is most effective when combined with targeted lifestyle modifications. For women over 40, certain lifestyle factors are disproportionately important.
Resistance training
This is the single most important lifestyle intervention for women over 40 who are losing weight. Resistance training preserves lean muscle mass during weight loss, maintains metabolic rate, and supports bone density. Two to three sessions per week is the standard recommendation, and it does not require a gym — bodyweight exercises and resistance bands are effective.
Protein intake
Higher protein intake — approximately 1.0 to 1.2 grams per kilogram of body weight daily — supports muscle preservation during weight loss. Many women under-consume protein, particularly at breakfast and lunch. Distributing protein evenly across meals maximizes its muscle-protective effect.
Sleep optimization
Poor sleep worsens insulin resistance and disrupts hunger hormones. Melatonin production decreases with age, making sleep disruption more common during perimenopause. Addressing sleep quality — whether through sleep hygiene, treatment of hot flashes, or other interventions — directly supports weight loss.
Stress management
Elevated cortisol directly promotes visceral fat storage. For women juggling career demands, family responsibilities, and hormonal changes, chronic stress is common. Stress management is not a luxury — it is a metabolic intervention.
Research consistently shows that medication combined with lifestyle modification produces significantly better outcomes than either approach alone. Medication addresses the biological barriers, while lifestyle changes build the foundation for long-term maintenance.
PEAK’s approach for women
At PEAK, we recognize that women over 40 need a different approach than a 25-year-old looking to lose weight. Our evaluation goes beyond BMI to understand the full metabolic picture.
- Full metabolic screening. We evaluate fasting glucose, insulin levels, HbA1c, lipid panel, thyroid function, and inflammatory markers — not just your weight and BMI.
- Hormonal status review. Understanding where you are in the perimenopause-to-menopause transition helps guide medication selection and set realistic expectations.
- Full medication review. We review every medication you are taking to identify interactions and optimize your overall treatment plan.
- Individualized medication selection. Your medication is chosen based on your specific risk-benefit profile, not a one-size-fits-all protocol.
- Ongoing monitoring. We track bone density markers, muscle mass indicators, and metabolic markers throughout treatment — not just the number on the scale.
- Adaptive treatment. As patients progress through perimenopause and menopause, medication needs may change. We adjust treatment proactively rather than reactively.
- Integrated lifestyle guidance. Medical treatment is paired with practical guidance on resistance training, protein intake, sleep, and stress management.
Important safety information: GLP-1 and GIP/GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda) carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or MEN 2. Contrave carries a black box warning for suicidal thoughts and is contraindicated in patients with seizure disorders or eating disorders. Phentermine is a Schedule IV controlled substance approved for short-term use only. Discuss your full medical history with your clinician before starting any weight loss medication.
Frequently asked questions
Is it harder to lose weight after 40?
Yes, due to metabolic, hormonal, and body composition changes. Basal metabolic rate decreases, muscle mass declines, and hormonal shifts promote visceral fat storage. However, prescription medications can significantly improve outcomes by addressing these biological changes directly. Women over 40 respond well to GLP-1s and other weight-loss medications — clinical trial data shows comparable efficacy across age groups.
Should I try HRT for weight loss?
HRT can help with menopausal symptoms and may reduce visceral fat accumulation, but it is not a weight-loss treatment on its own. It is best used alongside dedicated weight-loss medication when appropriate. If you are experiencing menopausal symptoms that are affecting your quality of life, HRT is worth discussing with your clinician — but do not expect it to drive significant weight loss by itself.
Is phentermine safe for women over 40?
Phentermine can be safe with proper cardiovascular screening. Women with controlled blood pressure and no heart disease can often use phentermine effectively. The key is thorough screening before prescribing and regular monitoring during treatment. PEAK includes cardiovascular evaluation as part of every initial assessment, and blood pressure and heart rate are checked at every follow-up visit.
Will weight-loss medication affect my hormones?
GLP-1 medications and Contrave do not significantly affect estrogen or progesterone levels. They work through entirely different pathways — appetite regulation, metabolic signaling, and glucose regulation. If you are on HRT or other hormonal medications, always inform your provider so they can coordinate your treatment plan. There are no known interactions between GLP-1 medications and standard HRT.
How much weight can women over 40 expect to lose with medication?
Clinical trial data shows women over 40 respond comparably to younger patients. Average weight loss by medication: approximately 15% with Wegovy (STEP 1, 68 weeks) and up to 22.5% with Zepbound (SURMOUNT-1, 72 weeks), phentermine produces 5–8%, and Contrave produces approximately 5–6%. Individual results vary based on starting weight, metabolic factors, medication adherence, and lifestyle modifications. Combining medication with resistance training and adequate protein intake tends to produce better results and preserve muscle mass.
Clinical references
- Kapoor E, Collazo-Clavell ML, Faubion SS. Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management. J Mid-life Health. 2017;8(3):106–117. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1): Subgroup analysis of women aged 40–65. N Engl J Med. 2021;384:989–1002. PubMed
- Greendale GA, Sternfeld B, Huang M, et al. Changes in Body Composition and Weight During the Menopause Transition. J Clin Endocrinol Metab. 2019;104(11):5401–5410. PubMed
- The North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. PubMed
